Abstract
A benefit-cost analysis of full continuum (FC) and partial continuum (PC) care was conducted on a sample of substance abusers from the State of Washington. Economic benefits were derived from client self-reported information at treatment entry and at 9 months postadmission using an augmented version of the Addiction Severity Index (ASI). Average (i.e., per client) economic benefits of treatment from baseline to follow-up for both FC and PC were statistically significant for most variables and in the aggregate. The overall difference in average economic benefit between FC and PC was positive ($8,053) and statistically significant, favoring FC over PC. The average cost of treatment amounted to $2,530 for FC and $1,138 for PC (p <.01). Average net benefits were estimated to be $17,833 (9.70) for FC and $11,173 (23.33) for PC, with values showing statistical significance (p <.05). Results strongly indicate that both treatment options generated positive and significant net benefits to society.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 609-633 |
| Number of pages | 25 |
| Journal | Evaluation Review |
| Volume | 24 |
| Issue number | 6 |
| State | Published - Dec 2000 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Social Sciences(all)
Cite this
Benefit-cost analysis of residential and outpatient addiction treatment in the state of Washington. / French, Michael; Salomé, Helena J.; Krupski, Antoinette; McKay, James R.; Donovan, Dennis M.; McLellan, A. Thomas; Durell, Jack.
In: Evaluation Review, Vol. 24, No. 6, 12.2000, p. 609-633.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Benefit-cost analysis of residential and outpatient addiction treatment in the state of Washington
AU - French, Michael
AU - Salomé, Helena J.
AU - Krupski, Antoinette
AU - McKay, James R.
AU - Donovan, Dennis M.
AU - McLellan, A. Thomas
AU - Durell, Jack
PY - 2000/12
Y1 - 2000/12
N2 - A benefit-cost analysis of full continuum (FC) and partial continuum (PC) care was conducted on a sample of substance abusers from the State of Washington. Economic benefits were derived from client self-reported information at treatment entry and at 9 months postadmission using an augmented version of the Addiction Severity Index (ASI). Average (i.e., per client) economic benefits of treatment from baseline to follow-up for both FC and PC were statistically significant for most variables and in the aggregate. The overall difference in average economic benefit between FC and PC was positive ($8,053) and statistically significant, favoring FC over PC. The average cost of treatment amounted to $2,530 for FC and $1,138 for PC (p <.01). Average net benefits were estimated to be $17,833 (9.70) for FC and $11,173 (23.33) for PC, with values showing statistical significance (p <.05). Results strongly indicate that both treatment options generated positive and significant net benefits to society.
AB - A benefit-cost analysis of full continuum (FC) and partial continuum (PC) care was conducted on a sample of substance abusers from the State of Washington. Economic benefits were derived from client self-reported information at treatment entry and at 9 months postadmission using an augmented version of the Addiction Severity Index (ASI). Average (i.e., per client) economic benefits of treatment from baseline to follow-up for both FC and PC were statistically significant for most variables and in the aggregate. The overall difference in average economic benefit between FC and PC was positive ($8,053) and statistically significant, favoring FC over PC. The average cost of treatment amounted to $2,530 for FC and $1,138 for PC (p <.01). Average net benefits were estimated to be $17,833 (9.70) for FC and $11,173 (23.33) for PC, with values showing statistical significance (p <.05). Results strongly indicate that both treatment options generated positive and significant net benefits to society.
UR - http://www.scopus.com/inward/record.url?scp=0034565765&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034565765&partnerID=8YFLogxK
M3 - Article
VL - 24
SP - 609
EP - 633
JO - Evaluation Review
JF - Evaluation Review
SN - 0193-841X
IS - 6
ER -